Precigen (PGEN) Current Assets (2012 - 2026)
Precigen (PGEN) posted quarterly Current Assets of $101.7 million for Q1 2026, up 20.18% year-over-year from $84.6 million in Q1 2025, and down 11.77% quarter-over-quarter from $115.2 million in Q4 2025.
Precigen (PGEN) Current Assets (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Current Assets for 15 consecutive years, with $101.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 20.18% year-over-year to $101.7 million; the TTM figure through Mar 2026 stood at $101.7 million (up 20.18% YoY), while the FY2025 annual figure was $115.2 million, up 12.52% from the prior year.
- Current Assets declined to $101.7 million in Q1 2026 per PGEN's latest filing, from $115.2 million in the prior quarter.
- Across five years, Current Assets topped out at $164.6 million in Q2 2022 and bottomed at $23.7 million in Q2 2024.
- Historically, Current Assets has averaged $100.6 million across 5 years, with a median of $102.4 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets slumped 77.55% — and 2025, when it jumped 275.5%.
- Precigen's Current Assets stood at $118.2 million in 2022, then tumbled by 41.81% to $68.8 million in 2023, then soared by 48.95% to $102.4 million in 2024, then rose by 12.52% to $115.2 million in 2025, then dropped by 11.77% to $101.7 million in 2026.
- Business Quant data shows PGEN's Current Assets at $101.7 million in Q1 2026, $115.2 million in Q4 2025, and $129.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn | 134.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.38 Mn |
| Mar 31, 2026 | 101.67 Mn |
| Dec 31, 2025 | 115.24 Mn |
| Sep 30, 2025 | 129.60 Mn |
| Jun 30, 2025 | 62.76 Mn |
| Mar 31, 2025 | 84.60 Mn |
| Dec 31, 2024 | 102.41 Mn |
| Sep 30, 2024 | 34.51 Mn |
| Jun 30, 2024 | 23.72 Mn |
| Mar 31, 2024 | 49.55 Mn |
| Dec 31, 2023 | 68.76 Mn |
| Sep 30, 2023 | 92.99 Mn |
| Jun 30, 2023 | 105.63 Mn |
| Mar 31, 2023 | 137.74 Mn |
| Dec 31, 2022 | 118.16 Mn |
| Sep 30, 2022 | 162.81 Mn |
| Jun 30, 2022 | 164.62 Mn |
| Mar 31, 2022 | 154.94 Mn |
| Dec 31, 2021 | 156.63 Mn |
| Sep 30, 2021 | 153.09 Mn |